On February 5, 2024, after serving for nearly five years on the Board of Directors of Sensei Biotherapeutics, Inc. Samuel Broder, MD notified the Company of his decision to resign from the Board, effective immediately. Dr. Broder has agreed to remain as a consultant to the Company, pursuant to which he will provide strategic guidance with respect to the science, clinical development, and regulatory pathways of the Company?s product candidates. On February 6, 2024, the Board approved a reduction in the number of directors on the Board from nine to eight and appointed Bill Ringo as Interim Chair of the Nominating and Corporate Governance Committee, each effective immediately.